Skip to main content

How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 31, 2025.

Official Answer by Drugs.com

Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

How It Works:

FDA Approval:

Lutathera was FDA-approved in January 2018 for the treatment of GEP-NETs, a rare group of cancers that develop in the:

It is currently approved for people ages 12 years and older.

References
  1. Lutathera [package insert]. 2024. Advanced Accelerator Applications USA, Inc. Accessed March 31, 2025 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55

See also:

Drug information

Related support groups